Overview

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Status:
RECRUITING

Trial end date:
2030-01-08

Target enrollment:

Participant gender:

Summary

This is an open label extension (OLE) study of an ongoing randomized controlled clinical study 218224 (Parent Study). The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.

Phase:

PHASE3

Details

Lead Sponsor:

GlaxoSmithKline

Collaborator:

ICON plc

Treatments:

belimumab